Olmesartan: Nursing Drug Guide, Sprue-Like Enteropathy & Hold Rules
Angiotensin II receptor blocker for hypertension: the bedside priority nurses must not miss is sprue-like enteropathy—severe chronic diarrhea with substantial weight loss months to years after olmesartan starts, often with villous atrophy—alongside the boxed warning for fetal injury, acute kidney injury risk with NSAIDs, and hyperkalemia when potassium-raising drugs stack on the MAR. Trend bowel pattern, weight, basic metabolic panel, blood pressure, and hold when enteropathy, pregnancy, or dangerous electrolyte shifts appear.
Labeling warns that severe, chronic diarrhea with substantial weight loss has occurred months to years after olmesartan initiation; intestinal biopsies may show villous atrophy. If these symptoms develop, exclude other etiologies and consider alternative antihypertensive therapy when no other cause is found. Separately: When pregnancy is detected, discontinue olmesartan as soon as possible. Monitor serum potassium and renal function—hyperkalemia and renal impairment may occur, especially with potassium-raising agents, NSAIDs, or dual renin-angiotensin system blockade.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Chronic watery diarrhea with unintended weight loss in a patient on olmesartan—even when blood pressure looks fine—can signal sprue-like enteropathy per labeling. Hold, notify the team, document bowel and weight trends, and reconcile other causes before the next dose. Pair that vigilance with basic metabolic panel potassium and serum creatinine checks and pregnancy screening for the boxed fetal toxicity warning.
Most common brand names
Benicar is the widely recognized brand for olmesartan medoxomil. Generic olmesartan is available as oral tablets in 5 mg, 20 mg, and 40 mg strengths per reviewed labeling. Fixed-dose combinations may pair olmesartan with hydrochlorothiazide or amlodipine—confirm whether combination therapy is intentional before questioning duplicate antihypertensive orders.
Perform medication reconciliation when patients transition between brand and generic formulations, combination products, and home versus inpatient regimens. Verify tablet strength on every pass—5 mg, 20 mg, and 40 mg are not interchangeable without a prescriber order.
Why we give it — Indications
U.S. prescribing information lists olmesartan medoxomil as an angiotensin II receptor blocker indicated for hypertension in adults and pediatric patients six years of age and older, alone or with other antihypertensive agents, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.
| Use | Detail |
|---|---|
| Adult hypertension (oral) | Initial 20 mg once daily when not volume-contracted; may increase to 40 mg after 2 weeks; doses above 40 mg do not appear to have greater effect |
| Pediatric hypertension (≥6 years) | 10 mg once daily if weight 20 to <35 kg, or 20 mg once daily if weight ≥35 kg; may titrate to max 20 mg (<35 kg) or 40 mg (≥35 kg) |
| Combination therapy | May be used alone or with other antihypertensive agents; may be given with or without food |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Olmesartan medoxomil is a prodrug hydrolyzed to olmesartan, which selectively blocks angiotensin II at the AT1 receptor—preventing vasoconstriction and aldosterone secretion without inhibiting kininase II (ACE). Unlike ACE inhibitors, olmesartan is not associated with increased dry cough from bradykinin accumulation. Blockade of the renin-angiotensin-aldosterone system lowers blood pressure but can reduce aldosterone-driven potassium excretion and affect renal perfusion in susceptible patients—nurses should monitor potassium and serum creatinine, especially with potassium-sparing diuretics or supplements.
Dosing overview
Individualize to volume status, renal function, and prescriber orders. Labeling emphasizes initiating under close supervision with consideration of a lower starting dose when intravascular volume may be depleted.
Renal impairment: No initial dosage adjustment recommended for moderate to marked renal impairment (creatinine clearance <40 mL/min) per U.S. labeling; AUC approximately tripled with severe impairment (CrCl <20 mL/min). BNF advises avoiding olmesartan if creatinine clearance is less than 20 mL/minute and limiting to maximum 20 mg daily if CrCl is 20–60 mL/minute—follow local prescribing guidance.
Hepatic impairment: No initial dosage adjustment recommended for moderate to marked hepatic dysfunction per U.S. labeling (AUC increased about 60%). BNF advises maximum 20 mg daily in moderate hepatic impairment and avoidance in severe impairment.
Pediatrics: Not shown effective for hypertension in children <6 years; use in children <1 year is not recommended per labeling.
Missed dose: Not specified in the reviewed prescribing information; follow prescriber or pharmacy guidance.
Onset, peak, and duration
- Absorption: Prodrug rapidly bioactivated to olmesartan; absolute bioavailability approximately 26%; peak plasma concentration at 1 to 2 hours
- Food: Does not affect bioavailability—may be given with or without food
- Half-life: Terminal elimination half-life approximately 13 hours; steady state within 3 to 5 days with once-daily dosing
- Metabolism: Virtually no further metabolism of olmesartan; not metabolized by cytochrome P450
- Excretion: About 35% to 50% recovered in urine, remainder in feces; crosses placenta; secreted in milk of lactating rats per labeling
Before you give it — Safety check
Pretreatment checks
- Latest basic metabolic panel: potassium, serum creatinine, BUN, sodium
- Blood pressure and orthostatic vitals—especially after first dose or in diuretic-treated patients
- Pregnancy status in patients of childbearing potential; boxed warning for fetal toxicity
- Bowel pattern, stool frequency, and recent weight trend—new chronic diarrhea or weight loss on long-term olmesartan
- Allergies and prior angioedema with ARBs or ACE inhibitors
- MAR scan for potassium-raising drugs, NSAIDs, lithium, colesevelam, and dual RAS blockade
Contraindications
- Do not coadminister aliskiren with olmesartan in patients with diabetes per labeling
- BNF lists biliary obstruction as a contraindication for olmesartan medoxomil
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| Agents raising potassium (spironolactone, supplements, salt substitutes, heparin) | May increase serum potassium—monitor potassium | Hold and notify when potassium exceeds limits; teach patients to avoid hidden potassium sources |
| ibuprofen and other NSAIDs | May reduce antihypertensive effect; in volume-depleted or elderly patients may worsen renal function including acute kidney injury | Monitor serum creatinine and blood pressure; question chronic NSAID use without prescriber approval |
| Lithium | Increased serum lithium and toxicity reported | Flag new lithium orders with ARBs; confirm monitoring plan with pharmacy |
| Dual RAS blockade (ACE inhibitor + ARB, or with aliskiren) | Increased hypotension, hyperkalemia, and renal impairment risk; generally avoid combined use | Verify intentional combination; trend basic metabolic panel and blood pressure closely |
| furosemide and other diuretics | Volume depletion increases hypotension risk at initiation | Initiate under close supervision; consider lower starting dose per labeling |
| Colesevelam hydrochloride | Reduces olmesartan exposure if given concurrently | Consider administering olmesartan at least 4 hours before colesevelam per labeling |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Oral only: Tablets 5 mg, 20 mg, or 40 mg. May be administered with or without food per labeling. Pediatric patients who cannot swallow tablets may receive an extemporaneous suspension prepared per labeling instructions—institutional protocols and product formulations may vary.
- Verify tablet strength (5 vs 20 vs 40 mg) before every administration
- Pair first doses or dose increases with blood pressure measurement and orthostatic assessment when volume depletion is possible
- Space olmesartan at least 4 hours before colesevelam when both are ordered
- Reconcile home olmesartan against inpatient combination products at admission, transfer, and discharge
- Confirm pregnancy screening or contraception counseling when applicable before continuing therapy
Labeling describes sprue-like enteropathy presenting as severe, chronic diarrhea with substantial weight loss months to years after initiation. Ask about bowel changes at every follow-up—even when blood pressure is controlled.
Expected therapeutic response
- Gradual blood pressure reduction—effect apparent after the first dose with near full effect by about 2 weeks per labeling
- Improved blood pressure control without symptomatic hypotension, orthostatic dizziness, or unintended weight loss
- Stable potassium and serum creatinine when potassium-raising drugs are intentionally balanced
- No progression of chronic watery diarrhea—worsening GI symptoms despite stable BP should trigger enteropathy evaluation
Red flags — Stop and act
Sprue-like enteropathy can mimic celiac disease or other GI disorders—do not dismiss chronic diarrhea simply because olmesartan is “just a blood pressure pill.”
- Severe chronic diarrhea with substantial weight loss developing months to years after olmesartan initiation—exclude other etiologies; consider alternative antihypertensive therapy per labeling
- Potassium above prescriber or protocol hold limit, peaked T waves, widened QRS, or new muscle weakness
- Acute rise in serum creatinine/BUN or oliguria suggesting acute kidney injury—especially with NSAIDs or dual RAS blockade
- Angioedema with facial swelling, lip or tongue swelling, or difficulty breathing—discontinue and escalate per anaphylaxis protocol
- Confirmed or suspected pregnancy—discontinue immediately per boxed warning
- Symptomatic hypotension or syncope after first dose in diuretic-treated or volume-depleted patients
- Generalized hives or anaphylactic symptoms postmarketing per labeling
Adverse effects
| Adverse effect | Notes (labeling / BNF) | Nursing response |
|---|---|---|
| Sprue-like enteropathy | Severe chronic diarrhea with substantial weight loss; villous atrophy on biopsy; months to years after initiation | Hold, notify prescriber, document weight and stool trends; consider alternative antihypertensive when no other etiology |
| dizziness | Most common adult trial adverse reaction (3% vs 1% placebo) | Orthostatic vitals; fall precautions; verify volume status |
| Hyperkalemia | Postmarketing; monitor potassium especially with renal insufficiency or potassium-raising drugs | Trend basic metabolic panel; hold and notify for clinically significant elevations |
| Hypotension / orthostatic symptoms | Anticipated in volume-/salt-depleted patients at initiation | Supine positioning and IV fluids per orders if symptomatic hypotension occurs |
| Renal impairment / acute kidney injury | Postmarketing increased creatinine and acute renal failure | Monitor serum creatinine; hold and notify when creatinine rises sharply |
| Angioedema | Postmarketing angioedema, anaphylactic reactions; facial edema reported in trials | Discontinue; emergency pathway for airway compromise |
| Rhabdomyolysis | Postmarketing report per labeling | Notify prescriber for unexplained muscle pain with dark urine or weakness |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
Limited human overdosage data are available in labeling. The most likely manifestations would be hypotension and tachycardia; bradycardia could occur if parasympathetic stimulation occurs.
Antidote
Not specified in the reviewed prescribing information — there is no listed specific reversing agent. Treatment is supportive.
Management per labeling
- If symptomatic hypotension occurs, initiate supportive treatment per protocol
- The dialyzability of olmesartan is unknown per labeling
- Monitor blood pressure, heart rate, mentation, and repeat basic metabolic panel as clinically indicated
- Contact local poison control or medical toxicology services per facility protocol for significant overdose or instability
Look-alike / sound-alike and error prevention
- Olmesartan vs other ARBs (valsartan, losartan, irbesartan)—similar names and classes; verify exact drug and strength
- Olmesartan vs omeprazole—unrelated proton-pump inhibitor; confirm indication and MAR entry
- 5 mg vs 20 mg vs 40 mg tablets—triple-check strength; pediatric and adult orders differ by weight and indication
- Combination products—olmesartan-hydrochlorothiazide or olmesartan-amlodipine fixed-dose tablets embed additional agents; scan for duplicate antihypertensive ingredients
- Duplicate ARB therapy—home olmesartan plus inpatient ARB or ACE inhibitor ordering errors; reconcile the MAR at every transition
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Enteropathy cue | Ask “Has your diarrhea or weight changed since starting this blood pressure medicine?” at every visit—not only at initiation |
| Potassium sources | Ask explicitly about salt substitutes and OTC potassium—patients may not list them as medications |
| First-dose hypotension | Volume-depleted patients need close supervision and possibly lower starting dose per labeling |
| No ACE cough | Olmesartan does not inhibit ACE—do not assume all RAAS drugs behave like ACE inhibitors |
| Pregnancy screening | Boxed warning—confirm contraception or pregnancy status in relevant patients before each new course |
| Ask pharmacy when | Chronic diarrhea on long-term olmesartan, dual RAS blockade, lithium overlap, or refractory hyperkalemia |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Pregnancy | Boxed fetal toxicity—discontinue when pregnancy detected; renin-angiotensin drugs can cause fetal renal failure and death |
| Volume-/salt-depleted patients | Symptomatic hypotension after initiation; initiate under close supervision with lower starting dose consideration |
| chronic kidney disease / renal artery stenosis | Renal function may deteriorate—monitor serum creatinine; severe renal impairment increases drug exposure |
| Long-term olmesartan users | Sprue-like enteropathy may present months to years after start—maintain bowel and weight surveillance |
| Elderly on diuretics/NSAIDs | Greater renal impairment risk when NSAIDs added—monitor serum creatinine closely |
| Lactation | No human milk data; labeling advises choosing to discontinue nursing or the drug |
| Black patients (hypertension) | Antihypertensive effect somewhat less in black patients per labeling—blood pressure still requires monitoring |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Bowel pattern, stool frequency, hydration status, and weight trend—especially on long-term olmesartan
- Serum potassium and renal function (serum creatinine, BUN)—periodically per labeling, especially with potassium-raising drugs
- Blood pressure and orthostatic vitals after initiation, dose changes, or when diuretics are concurrent
- ECG or telemetry when hyperkalemia is suspected or potassium is borderline high
- Signs of angioedema, dizziness, or recurrent hypertension symptoms
Document
- Dose, time, tablet strength, indication, and blood pressure response
- Latest basic metabolic panel values, weight, and any hold parameters triggered
- Chronic diarrhea onset, severity, and weight change timeline when enteropathy is suspected
- Pregnancy status or contraception counseling when applicable
- Patient teaching on diarrhea reporting, salt substitutes, and when to report swelling or weakness
Patient teaching
- Report ongoing watery diarrhea, nausea, unintended weight loss, muscle weakness, palpitations, dizziness, swelling of face or lips, or decreased urination promptly
- Do not use potassium-based salt substitutes or start potassium supplements unless prescriber directs—risk of dangerous hyperkalemia with olmesartan
- Do not take OTC NSAIDs without asking your prescriber—they can raise blood pressure and harm kidneys
- Use effective contraception and notify your care team immediately if pregnancy is possible—this medicine can harm an unborn baby
- Rise slowly from sitting or lying down to reduce orthostatic dizziness
- Keep follow-up appointments for blood tests and weight checks that monitor kidney function and electrolytes
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Known olmesartan allergy, angioedema, or anaphylaxis with ARBs
- Severe chronic diarrhea with substantial weight loss suggesting sprue-like enteropathy—hold pending evaluation
- Potassium above institutional hold parameters or ECG changes consistent with hyperkalemia
- Confirmed or suspected pregnancy—discontinue per boxed warning
- Symptomatic hypotension, syncope, or acute mental status change suggesting hypoperfusion
- Marked serum creatinine/BUN rise or oliguria suggesting acute kidney injury
- Scheduled dose when dangerous potassium-raising overlap has not been clarified
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Olmesartan is a potent once-daily ARB for hypertension—and a drug where nurses can prevent harm by treating chronic diarrhea and weight loss as medication-safety signals, not background noise, while still trending potassium and renal function.
1. Check-before-you-give protocol
- Right patient, drug, dose, route, time—and right basic metabolic panel within acceptable timeframe when ordered
- Verify tablet strength (5 vs 20 vs 40 mg) matches the MAR
- Review bowel pattern and weight since last assessment—especially if olmesartan started months ago
- Scan for spironolactone, potassium supplements or salt substitutes, NSAIDs, lithium, and dual RAS agents
- Confirm pregnancy status when applicable before administration
2. High-alert and safety badge
Not on all institutional high-alert lists, but sprue-like enteropathy, boxed fetal toxicity, and hyperkalemia risk require bowel/weight surveillance, pregnancy screening, and hold rulesLabeling emphasizes monitoring renal function and serum potassium during therapy.
3. Clinical workflow: hold and question rules
- If chronic watery stools and weight loss appear on long-term olmesartan, hold the next dose and notify the team before attributing symptoms to diet alone
- If potassium is rising across shifts, hold the next dose and page the team before giving another ARB dose
- If serum creatinine jumps while NSAIDs are used PRN, clarify whether olmesartan and NSAID overlap is safe
4. Critical teach-back questions
- “What bowel or weight changes should you report while taking this blood pressure medicine?” (Patient should name chronic diarrhea and unintended weight loss.)
- “What should you avoid at the dinner table?” (Patient should name potassium-based salt substitutes and unauthorized potassium pills.)
5. Care coordination
Pharmacist: Combination product review, enteropathy evaluation support, potassium-raising interaction screening, and hyperkalemia management protocols
Prescriber: Notify for sprue-like enteropathy symptoms, hyperkalemia with ECG changes, acute creatinine rise, angioedema, symptomatic hypotension, or pregnancy
🧠 Quick mental checklist
- Has this patient had chronic diarrhea or weight loss since starting olmesartan—even months later?
- What is the latest potassium—and is a salt substitute on the MAR?
- Is this a 5, 20, or 40 mg tablet—and does volume status support that dose?
- Has creatinine risen since olmesartan started or since NSAID use?
- Could this patient be pregnant?
Olmesartan NCLEX practice questions
Practice NCLEX-style clinical judgment practice for olmesartan using a tabbed long-term therapy case (MAR, labs, I&O, nursing notes), then priority action, cue recognition SATA, symptom trend SATA, matrix urgency sorting, volume-depletion initiation judgment, and overdose cloze—with explicit evaluate outcomes items after enteropathy intervention.
Select a tab to view MAR, labs, I&O, and nursing note details for this case.
- Olmesartan 40 mg PO daily — due 0900 (home dose continued × 14 months)
- Amlodipine 5 mg PO daily — given 0700
- Acetaminophen 650 mg PO q6h PRN — none in 24 h
- Albumin 4.1 → 3.2 g/dL over 8 weeks
- Potassium 4.2 mEq/L; creatinine stable at 1.0 mg/dL; BUN 18 mg/dL
- Hemoglobin 11.8 g/dL (baseline 13.4 g/dL)
- Admission weight 78 kg → 69 kg over 10 weeks (−9 kg)
- Stools: 6–8 watery bowel movements daily × 6 weeks per patient report
- Oral intake poor × 2 weeks; urine output adequate
- 67-year-old with hypertension; olmesartan started 14 months ago with good home BP readings
- 0840: reports fatigue, abdominal cramping, and watery diarrhea; denies fever or bloody stools
- 0845: outpatient GI workup pending; celiac serology negative; biopsy not yet resulted
- 0900: olmesartan 40 mg due; nurse reviewing case tabs before administration
Answer key & rationale
Frequently asked questions
What should I check before giving olmesartan?
Review bowel pattern and recent weight trend for chronic diarrhea or unintended weight loss, check the latest basic metabolic panel (potassium, creatinine, BUN), confirm blood pressure and orthostatic symptoms, verify pregnancy status in patients of childbearing potential, scan the MAR for potassium-raising drugs, NSAIDs, lithium, colesevelam, and dual renin-angiotensin system blockade, and match tablet strength (5, 20, or 40 mg) to the order.
When should nurses hold olmesartan?
Hold and contact the prescriber or pharmacist when severe chronic diarrhea with substantial weight loss suggests sprue-like enteropathy, potassium exceeds protocol limits or ECG changes suggest hyperkalemia, creatinine rises sharply or acute renal failure is suspected, symptomatic hypotension occurs—especially in volume-depleted patients—pregnancy is confirmed or suspected, angioedema or anaphylaxis develops, or known hypersensitivity exists. Do not restart until the team clarifies the plan.
What is olmesartan sprue-like enteropathy?
Labeling warns that severe, chronic diarrhea with substantial weight loss has been reported months to years after olmesartan initiation; intestinal biopsies may show villous atrophy. If a patient develops these symptoms, exclude other etiologies and consider alternative antihypertensive therapy when no other cause is identified.
Can olmesartan be used in pregnancy?
No. Labeling carries a boxed warning for fetal toxicity: when pregnancy is detected, discontinue olmesartan as soon as possible. Drugs acting on the renin-angiotensin system can cause fetal injury and death, including oligohydramnios, renal failure, and skull hypoplasia. Use effective contraception counseling and immediately notify the prescriber if pregnancy is possible.
Is there an antidote for olmesartan overdose?
No specific antidote is listed in the reviewed prescribing information. Limited data suggest overdosage would most likely cause hypotension and tachycardia; bradycardia could occur. The dialyzability of olmesartan is unknown. Treatment is supportive—manage blood pressure and heart rate per protocol. Contact local poison control or medical toxicology services per facility guidance for significant overdose.
References
- U.S. National Library of Medicine. OLMESARTAN MEDOXOMIL tablet — SPL product labeling. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5972c6fd-08e3-4189-a894-1ba220b57e80
- Joint Formulary Committee. Olmesartan medoxomil monograph. BNF (NICE).https://bnf.nice.org.uk/drugs/olmesartan-medoxomil/
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.